synergistic effect

Rufigallol (AI3-00865) is an electron-deficient disk-shaped molecule with six hydroxyl groups and is a good unit for inducing the formation of DLC from non-planar AIE molecules, an anthraquinone derivative.Rufigallol induces the acquisition of DLC properties, while the introduction of TPE groups gives the molecular structure good fluorescence in the aggregated state.The remarkable synergistic in vitro antimalarial effect, in vivo with vitamin C and ketones was synergistic and showed antimalarial activity.

JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor. JAK3/ BTk-in-2 inhibits both BTK and JAK3, which are two important targets IN autoimmune diseases. JAK3/ BTk-in-2 simultaneously inhibits the BTK/JAK3 signaling pathway, showing a synergistic effect. JAK3/ BTk-in-2 has the potential to treat diseases associated with abnormal JAK3 and BTK activity.

JAK3/ BTk-in-1 is a dual JAK3/BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two important targets in autoimmune diseases. JAK3/ BTk-in-1 simultaneously inhibited the BTK/JAK3 signaling pathway, showing a synergistic effect. JAK3/ BTK-in-1 is a potential compound for the treatment of immune-related diseases, such as autoimmune diseases, certain types of cancer (including lymphoma and leukemia), and other diseases that may be characterized by an unbalanced immune response.

Brusatol (NSC-172924) is a natural product isolated from the Brucea javanica plant. It inhibits Nrf2.

HL23 is a histone deacetylase (HDAC) inhibitor that effectively targets hepatocellular carcinoma (HCC). It promotes acetylation at the TXNIP promoter and increases TXNIP expression, which in turn modulates potassium channel activity and induces TXNIP-dependent potassium deficiency. Additionally, HL23 impedes the advancement and spread of HCC and demonstrates a synergistic effect when combined with Sorafenib, exhibiting greater potency than the duo of Sorafenib and Vorinostat [1].

trans-Cyclohexane-1,2-diol (trans-1,2-Cyclohexanediol) has a synergistic retardation effect on percutaneous absorption and penetration of metronidazole (MTZ).

18:0 EPC chloride, a synthetic cationic phospholipid, significantly enhances eugenol's inactivation effect on Escherichia coli [1] when used at critical synergistic concentrations ranging from 2.34 to 2.93 μM.

Glabrene, Liquiritin apioside, neolicuroside, and 18α²-glycyrrhetic acid are the predominant phenolic derivatives partitioning at the interface and most likely the major contributors to the notable synergistic antioxidant activity when coupled with pea pr

JAK3/BTK-IN-5 is a potent inhibitor of JAK3/BTK. where BTK and JAK3 are two key targets in autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway has a synergistic effect and JAK3/BTK-IN-5 has potential research value for JAK3 kinase and/or BTK-related diseases.

JAK3/BTK-IN-3 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets in autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway has a synergistic effect and JAK3/BTK-IN-3 has shown potential for the investigation of JAK3 kinases and/or BTK-related diseases.

DNA-PK-IN-3 is a highly potent inhibitor of DNA-PK. This compound exerts a synergistic effect when combined with radiotherapy and chemotherapy, resulting in enhanced therapeutic outcomes and significant inhibition of tumor growth. Furthermore, DNA-PK-IN-3 demonstrates remarkable efficacy in reducing damage to normal cells, effectively minimizing adverse side effects. Due to these compelling properties, DNA-PK-IN-3 holds great potential for cancer research applications[1].

Ki23057 is a a FGFR2 inhibitor, which enhances the chemosensitivity of drug-resistant gastric cancer cell lines when used in combination with chemotherapeutic drugs. Ki23057 might be therapeutically promising for treating drug-resistant gastric cancer cells, especially when used in combination with SN38, PTX, or VP16. The apoptosis process might be the main mechanism underlying the synergistic effect of these combinations. The ERCC1 and p53 genes may play an integral role in the synergism between Ki23057 and chemotherapeutic agents in drug-resistant cell lines. (source: Cancer Lett. 2011 Aug 1;307(1):47-52).

JAK3/BTK-IN-4 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets in autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signaling pathway has a synergistic effect and JAK3/BTK-IN-4 has potential for JAK3 kinase and/or BTK-related diseases.

Isoreserpiline, an indole alkaloid discovered in R. tetraphylla, exhibits a range of biological activities. This compound enhances the antibacterial efficacy of nalidixic acid against both nalidixic acid-sensitive and -resistant E. coli strains through a synergistic effect. Additionally, at a dosage of 25 mg/kg, it mitigates amphetamine-induced hyperactivity in mice.

Coriatin and corianin demonstrate synergistic effect to insecticidal activity of tutin againstarmyworm.

Z1078601926 is an allosteric inhibitor of the human dopamine transporter (hDAT) and exhibits a synergistic effect when combined with Nomifensine [1].

L0909 is an orally available inhibitors of Hepatitis C virus with a novel mechanism of action (EC50 = 0.022 μM, SI > 600). L0909 could block HCV replication by acting on the HCV entry stage. The high sensitivity to clinical resistant HCV mutants and synergistic effect with clinical drugs were observed for this compound. L0909 as a promising HCV entry inhibitor for single or combinational therapeutic potential.

AS2575959 is a novel GPR40 agonist, exhibiting glucose metabolism improvement and synergistic effect with sitagliptin on insulin and incretin secretion.

Lyoniside and saracoside are cytotoxic to promastigotes and intracellular amastigotes, they demonstrate strong anti-leishmanial efficacies in BALB/c mice model of leishmaniasis, suggests that these two compounds potential anti-leishmanial candidates. The

CMP3a is a NEK2 kinase inhibitor. CMP3a efficiently attenuated GBM growth in a mouse model and exhibited a synergistic effect with radiotherapy. Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase E

Quorum Sensing-IN-2 (compound 23e) is a quorum sensing inhibitor that curtails bacterial pathogenicity without impeding growth. It demonstrates minimal hemolytic activity while effectively inhibiting bacterial infections and exhibits a synergistic effect when combined with Ciprofloxacin in a P. aeruginosa PAO1-infected bacteremia model [1].

Corianin and coriatin demonstrate synergistic effect to insecticidal activity of tutin againstarmyworm.

Dehydrobruceine B, a quassinoid isolated from Brucea javanica, demonstrates a synergistic effect with Cisplatin in inducing apoptosis through the mitochondrial pathway. It enhances the expression of apoptosis-inducing factor (AIF) and Bax while inhibiting Keap1-Nrf2 [1].

Bovine Growth Hormone-Releasing Factor (bGRF(1-44)-NH2), commonly referred to as bovine GHRF, is a compound that stimulates the release of bovine growth hormone (GH). It has been found to exhibit a synergistic effect when combined with Hydrocortisone, enhancing its efficacy in promoting GH release [1] [2].

CHS-828 nicotinate is a CHS-828 salt with Nicotinic acid.. CHS-828 also known as GMX-1778, is a potent and selective NAMPT inhibitor. CHS-828 inhibits cellular synthesis of NAD. CHS 828 kill tumour cells by inhibiting the nuclear factor-kappaB translocation but unlikely through down-regulation of proteasome. CHS 828 has shown promising anticancer activity in experimental tumor models and primary cultures of cancer cells from patients. CHS 828 showed a synergistic effect with melphalan in 67%, doxorubicin in 47%, etoposide in 38% and Ara-C in 14% of AML samples.

CGP 43182 is an effective inhibitor of group IIA secretory phospholipase A2 (Group IIA sPLA2) activity in vitro, which can be used to prevent the synergistic effect of pro-inflammatory genes stimulated by cytokines mediated by NFkappaB.